Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. J. Tevaarwerk
Capecitabine and Oxaliplatin in Combination as First- Or Second-Line Therapy for Metastatic Breast Cancer: A Wisconsin Oncology Network Trial
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Related publications
Individually Tailored Treatment With Epirubicin and Paclitaxel With or Without Capecitabine as First-Line Chemotherapy in Metastatic Breast Cancer: A Randomized Multicenter Trial
Breast Cancer Research and Treatment
Cancer Research
Oncology
Capecitabine in Combination With Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: An Observational Study
Pathology and Oncology Research
Medicine
Forensic Medicine
Pathology
Oncology
Cancer Research
Sorafenib in Combination With Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-Line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
Clinical Cancer Research
Cancer Research
Oncology
Capecitabine and Irinotecan as First- Line Chemotherapy for Patients With Metastatic Colorectal Cancer
Journal of IMAB - Annual Proceeding (Scientific Papers)
Dentistry
Capecitabine (Cap) Combined With Bevacizumab (Bev) With or Without Vinorelbine (Vin) in First-Line Metastatic Breast Cancer (MBC): First Safety Results From the Randomized CARIN Trial.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial
Breast Care
Surgery
Oncology
Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
Design of RESILIENCE: A Phase 3 Trial Comparing Capecitabine in Combination With Sorafenib or Placebo for Treatment of Locally Advanced or Metastatic HER2-negative Breast Cancer
Breast Cancer Research
Cancer Research
Oncology
Exemestane as Third and Fourth Line Hormonal Therapy for Metastatic Breast Cancer
Breast Cancer Research
Cancer Research
Oncology
